![]()
Greetings! This week’s editorial focus is on CDMOs, one of the biopharma industry’s keystone species. Yet, not all CDMOs are created equal, as Herman Bozenhardt explains on the “Better Biopharma” podcast.
While outsourced manufacturing has become standard practice, deciding who to partner with is not always straightforward. In this guest column, consultant Tamika Drummond, Ph.D., outlines key considerations for selecting the right CDMO.
Some product types still lack viable CDMO options, but it’s important to remember that CDMOs respond to the market demand rather than create it. As my colleague Louis Garguilo writes in his editorial, “Programs unattractive to CDMOs under one manufacturing paradigm may become viable under another.”
In case you missed it, out now is GlobalData’s “April 2026 CDMO Opportunities And Threats Report.” This monthly report identifies CDMOs that may be impacted by key events affecting their clients (e.g., acquisitions, licenses, approvals, etc.).
Be sure to check out some selected content from our partners below! And if you’re a fan of the “Better Biopharma” podcast, take this 60-second survey to help shape future coverage.
Tyler Menichiello
Chief Editor, Bioprocess Online
Greetings! This week’s editorial focus is on CDMOs, one of the biopharma industry’s keystone species. Yet, 
